Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Opioid plaintiffs fight bid to disqualify U.S. judge before trial

Published 09/16/2019, 03:35 PM
Updated 09/16/2019, 03:41 PM
Opioid plaintiffs fight bid to disqualify U.S. judge before trial

By Nate Raymond

(Reuters) - Lawyers for cities and counties suing drug companies over the opioid epidemic on Monday objected to a bid by pharmaceutical distributors and pharmacies to disqualify the federal judge overseeing the cases, saying it had no basis and came too late.

The plaintiffs' lawyers moved swiftly to fight the request companies including AmerisourceBergen Corp (N:ABC), Cardinal Health Inc (N:CAH) and McKesson Corp (N:MCK) had made on Saturday for U.S. District Judge Dan Polster in Cleveland, Ohio, to step aside from the litigation.

In Monday's brief, lawyers for the plaintiffs said the defendants had waived their ability to seek Polster's recusal, noting they were relying on statements he made more than a year ago to belatedly seek his disqualification.

"If these Defendants really thought recusal was necessary, they were required to raise the issue sooner - much sooner," the plaintiffs' lawyers wrote.

More than 2,500 lawsuits by state and local governments are pending nationally, accusing drug manufacturers of deceptively marketing opioids in ways that downplayed their risks, and drug distributors of failing to detect and halt suspicious orders.

The companies deny wrongdoing. Nearly 2,100 of the lawsuits are before Polster, while others are in state courts.

The companies had argued in Saturday's motion that Polster, who has long pushed for a settlement that could "do something meaningful to abate this crisis," had made a series of public statements since 2018 that could cause a reasonable person to question his impartiality.

They said those statements, made in court hearings and media interviews, raised the prospect that he had improperly prejudged their liability ahead of the first trial on Oct. 21 involving two Ohio counties seeking $8 billion.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

In Monday's brief, the plaintiffs' lawyers said the companies did not take action when Polster made those comments and actively participated in court-overseen settlement talks without objection.

Polster "has at no time expressed improper or biased views about the liability of any defendant, much less views based on extra-judicial sources," the lawyers wrote.

The companies who joined Saturday's motion also include CVS Health Corp (N:CVS) and Walmart Inc (N:WMT). The defendants did not respond to requests for comment.

Opioids were involved in 400,000 overdose deaths from 1999 to 2017, according to the U.S. Centers for Disease Control and Prevention.

OxyContin maker Purdue Pharma, one of the lead defendants, filed for bankruptcy protection on Monday after reaching a tentative deal to resolve claims in the federal litigation and by 24 U.S. states.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.